PASIREOTIDE
![PASIREOTIDE Structure](CAS/20210111/GIF/396091-73-9.gif)
- CAS No.
- 396091-73-9
- Chemical Name:
- PASIREOTIDE
- Synonyms
- SOM 320;SOM 230;Signifor;PASIREOTIDE;SOM 230;SOM 320;Pasireotide (SOM-230);Pasireotide Acetate(net);CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-);Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl];[(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
- CBNumber:
- CB02667889
- Molecular Formula:
- C58H66N10O9
- Molecular Weight:
- 1047.23
- MOL File:
- 396091-73-9.mol
- Modify Date:
- 2024/3/27 11:49:37
Boiling point | 1351.4±65.0 °C(Predicted) |
---|---|
Density | 1.36±0.1 g/cm3(Predicted) |
storage temp. | Store at -20°C |
solubility | Soluble in DMSO |
form | Powder |
pka | 11.86±0.46(Predicted) |
Sequence | cyclo[Tyr(Bzl)-Phe-Hyp(Bom)-Phg-D-Trp-Lys] |
CAS DataBase Reference | 396091-73-9 |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() ![]() ![]() GHS08,GHS07,GHS09 |
---|---|
Signal word | Warning |
Hazard statements | H400-H315-H361-H410-H319 |
Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P-P273-P391-P501-P273-P391-P501 |
PASIREOTIDE Chemical Properties,Uses,Production
Description
In April 2012, the European Commission approved pasireotide for the treatment of Cushing’s Disease (CD) in adult patients who have not responded to surgical interventionor forwhomsurgery is not anoption.Pasireotide was approved for the same indication by the US FDA in December of 2012. Pasireotide (also known as SOM230) is a cyclohexapeptide that acts as a somatostatin analogue to inhibit the release of ACTH. Somatostatins are cyclic peptides of 14 and 28 amino acids that play animportant role inregulating endocrineandexocrine release inmany tissues through an inhibitory mechanism. There are five known subtypes of somatostatin receptors (SSTRs). Natural somatostatins bind with high affinity to all five subtypes, however, their therapeutic use is limited by rapid degradation in plasma. Pasireotide arose fromefforts to identify a somatostatinmimetic with long-lasting inhibitory effects. Starting with a 14-amino acid somatostatin peptide, a systematic alanine scan revealed residues that were essential for receptor sub-type binding, including key b-turn regions and adjacent residues. Placing the key structural elements as unnatural amino acids in a cyclohexapeptide backbone gave pasireotide.
Uses
Pasireotide can be used in biological study of long-term treatment of Cushing''s disease with pasireotide, 5-yr results from open-label extension study of Phase III trial.
Clinical Use
Pasireotide, also known as SOM230, is a cyclic, hexameric peptide developed by Novartis which exhibits somatostatin-like activity as an antisecretory agent used in the treatment of Cushing’s disease. Pasireotide activates a broad range of somatostatin receptors, and in particular displays a significantly higher binding affinity for somatostatin receptors 1, 3, and 5 than its competitor somatostatin-mimic octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. Pasireotide is more potent than somatostatin in inhibiting the secretion of human growth hormone (HGH), glucagon, and insulin.
PASIREOTIDE Preparation Products And Raw materials
Raw materials
Preparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +8617865335152 | China | 10991 | 58 | Inquiry |
Nantong Guangyuan Chemicl Co,Ltd | +undefined17712220823 | China | 616 | 58 | Inquiry |
Alpha Biopharmaceuticals Co., Ltd | +86-15542445688 | China | 888 | 58 | Inquiry |
Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 | China | 10311 | 58 | Inquiry |
BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
Shanghai Longyu Biotechnology Co., Ltd. | +8619521488211 | China | 2534 | 58 | Inquiry |
career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29825 | 58 | Inquiry |
Related articles
- Pasireotide for Cushing's disease
- Pasireotide is a man-made protein that is similar to a hormone in the body called somatostatin. Pasireotide is used to treat ....
- Apr 29,2022
- A synthetic polypeptide drug:Pasireotide
- Pasireotide is a synthetic polypeptide analogue of somatostatin that resembles the native hormone in its ability to suppress l....
- Dec 29,2021